Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) EBITDA Margin: 2017-2025

Historic EBITDA Margin for Puma Biotechnology (PBYI) over the last 8 years, with Sep 2025 value amounting to 17.57%.

  • Puma Biotechnology's EBITDA Margin fell 984.00% to 17.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.83%, marking a year-over-year increase of 253.00%. This contributed to the annual value of 13.44% for FY2024, which is 42.00% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's EBITDA Margin is 17.57%, which was up 38.86% from 12.66% recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's EBITDA Margin registered a high of 27.41% during Q3 2024, and its lowest value of -31.16% during Q2 2021.
  • In the last 3 years, Puma Biotechnology's EBITDA Margin had a median value of 12.66% in 2025 and averaged 12.01%.
  • As far as peak fluctuations go, Puma Biotechnology's EBITDA Margin tumbled by 4,126bps in 2021, and later surged by 5,142bps in 2022.
  • Quarterly analysis of 5 years shows Puma Biotechnology's EBITDA Margin stood at -0.91% in 2021, then spiked by 1,234bps to 11.43% in 2022, then surged by 907bps to 20.50% in 2023, then spiked by 212bps to 22.62% in 2024, then crashed by 984bps to 17.57% in 2025.
  • Its last three reported values are 17.57% in Q3 2025, 12.66% for Q2 2025, and 8.66% during Q1 2025.